Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of M254 in healthy volunteers and adults with immune thrombocytopenia
NL-OMON49624Phase 2Completed
- Sponsor
- Momenta Pharmaceuticals
- Start
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of m254, sponsored by Momenta Pharmaceuticals. Started Jan 2019; status: completed.
02
Drugs
m254
Beyond the preview
Go deeper on NL-OMON49624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49624.